Aurinia Pharmaceuticals Inc. (IKAP.F)
- Previous Close
7.00 - Open
6.98 - Bid 7.08 x 85900
- Ask 7.26 x 81100
- Day's Range
6.98 - 7.06 - 52 Week Range
4.45 - 9.73 - Volume
185 - Avg. Volume
21 - Market Cap (intraday)
977.234M - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
176.60 - EPS (TTM)
0.04 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
www.auriniapharma.comRecent News: IKAP.F
View MorePerformance Overview: IKAP.F
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IKAP.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IKAP.F
View MoreValuation Measures
Market Cap
986.89M
Enterprise Value
740.46M
Trailing P/E
200.02
Forward P/E
16.10
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.97
Price/Book (mrq)
2.90
Enterprise Value/Revenue
3.57
Enterprise Value/EBITDA
26.43
Financial Highlights
Profitability and Income Statement
Profit Margin
2.45%
Return on Assets (ttm)
1.42%
Return on Equity (ttm)
1.52%
Revenue (ttm)
235.13M
Net Income Avi to Common (ttm)
5.75M
Diluted EPS (ttm)
0.04
Balance Sheet and Cash Flow
Total Cash (mrq)
358.44M
Total Debt/Equity (mrq)
21.03%
Levered Free Cash Flow (ttm)
62.94M